GlassScriptPhysician profile
Daniel C Terveen
NPI 1053791715
$520,593.03
in general payments reported to CMS, 2019-2025
26 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $2,026 · 2021: $1,781 · 2022: $872 · 2023: $513K · 2024: $1,239 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $510K · Food and Beverage: $3,651 · Consulting Fee: $1,856 · Travel and Lodging: $304 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $509,570.87 |
| Food and Beverage | $3,650.83 |
| Consulting Fee | $1,856.25 |
| Travel and Lodging | $303.73 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $514,235.46 | 2019-2025 | Idose Tr, Idose, Idosetr |
| Alcon Vision LLC | $3,608.89 | 2019-2025 | Clareon, Centurion, Argos |
| Sight Sciences, INC. | $329.70 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $272.40 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $244.49 | 2021-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $218.31 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $179.95 | 2023-2025 | Xiidra, Ic-8 Apthera Iol, Envista Envy Iol |
| Hoya Surgical Optics, INC | $178.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $148.69 | 2021-2025 | Acthar |
| Abbvie INC. | $141.99 | 2023-2025 | Vuity |
| Dompe US, INC. | $139.93 | 2022-2025 | Oxervate |
| Allergan, INC. | $126.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $123.57 | 2021-2024 | Cequa, Xelpros |
| Biotissue Holdings INC. | $115.01 | 2023-2025 | |
| Amgen INC. | $95.82 | 2024 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $91.11 | 2024-2025 | Vevye, Natacyn |
| Tarsus Pharmaceuticals, INC. | $81.36 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $80.21 | 2024 | Tecnis Iol, Healon Duet Pro, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $48.81 | 2022-2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Carl Zeiss Meditec USA, INC. | $34.22 | 2021 | |
| Rxsight INC | $25.59 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.25 | 2021 | |
| Kala Pharmaceuticals, INC. | $20.09 | 2021 | |
| Omeros Corporation | $16.58 | 2021 | |
| Horizon Therapeutics Plc | $13.59 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Terveen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.